Voyager Therapeutics Inc
NASDAQ:VYGR
Voyager Therapeutics Inc
Revenue
Voyager Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
Revenue
$80m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Voyager Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Voyager Therapeutics Inc
Breakdown by Segments
Voyager Therapeutics Inc
|
Total Revenue:
80m
USD
|
|
Represents Information Pertaining To Single R...:
80m
USD
|
Voyager Therapeutics Inc
Glance View
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.
See Also
What is Voyager Therapeutics Inc's Revenue?
Revenue
80m
USD
Based on the financial report for Dec 31, 2024, Voyager Therapeutics Inc's Revenue amounts to 80m USD.
What is Voyager Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
-5%
Over the last year, the Revenue growth was -68%. The average annual Revenue growth rates for Voyager Therapeutics Inc have been 29% over the past three years , -5% over the past five years .
You don't have any saved screeners yet